Logo

American Heart Association

  2
  0


Final ID: MDP469

Traditional Risk Factors, Cardiovascular Health, and Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis

Abstract Body (Do not enter title and authors here): Introduction: One in five individuals have elevated lipoprotein(a) [Lp(a)], an inheritable risk factor that is causally associated with atherosclerotic cardiovascular disease (ASCVD). Whether individuals with elevated Lp(a) derive similar benefit from control of ASCVD risk factors has not been well-studied.

Hypothesis: The magnitude of benefit associated with optimal cardiovascular health will be similar across the spectrum of Lp(a).

Aim: To assess the association of traditional risk factor burden and Life’s Simple 7 (LS7) score with incident ASCVD across Lp(a) values.

Methods: We studied 6,676 participants from the Multi-Ethnic Study of Atherosclerosis who underwent Lp(a) testing and were followed for incident ASCVD events (coronary heart disease and stroke). Elevated Lp(a) was defined as >50 mg/dL. As defined by the American Heart Association, LS7 metrics included smoking, physical activity, body mass index, diet, total cholesterol, blood pressure, and glucose. Multivariable Cox proportional hazards regression assessed the association of traditional risk factor burden and LS7 score (poor: 0-8, average: 9-10, optimal: 11-14) with incident ASCVD for individuals with and without elevated Lp(a) during a median follow-up of 17.7 years.

Results: The mean age was 62.1 years, 53% were women, and 61% were non-white. The median Lp(a) was 17 mg/dL and 20% had Lp(a) >50 mg/dL. Individuals with Lp(a) >50 mg/dL had the highest burden of traditional risk factors except cigarette smoking. Compared to those with a poor LS7 score, those with an optimal LS7 score had a lower ASCVD risk that was significant for participants with Lp(a) <50 mg/dL (HR=0.37, 95% CI: 0.25-0.55), but borderline significant for participants with Lp(a) >50 mg/dL (HR=0.41, 95% CI: 0.16-1.02). Individuals with Lp(a) >50 mg/dL had the highest absolute event rates across all LS7 categories, and there was no significant interaction between Lp(a) and LS7 score on incident ASCVD (p-interaction=0.64, Figure).

Conclusions: Participants with an optimal LS7 score had similar reduction in ASCVD risk regardless of their Lp(a) burden. These results emphasize the importance of a healthy lifestyle and ASCVD risk factor control among patients with elevated Lp(a).
  • Razavi, Alexander  ( Emory University , Atlanta , Georgia , United States )
  • Reyes, Mikaila  ( University of California San Diego , La Jolla , California , United States )
  • Wilkins, John  ( Northwestern University , Chicago , Illinois , United States )
  • Szklo, Moyses  ( JOHNS HOPKINS UNIV , Baltimore , Maryland , United States )
  • Tsai, Michael  ( UNIVERSITY MINNESOTA , Minneapolis , Minnesota , United States )
  • Whelton, Seamus  ( Johns Hopkins , Baltimore , Maryland , United States )
  • Sperling, Laurence  ( EMORY UNIV , Atlanta , Georgia , United States )
  • Tsimikas, Sotirios  ( UNIV CALIFORNIA SAN DIEGO , La Jolla , California , United States )
  • Bhatia, Harpreet  ( University of California San Diego , San Diego , California , United States )
  • Author Disclosures:
    Alexander Razavi: DO NOT have relevant financial relationships | Mikaila Reyes: DO NOT have relevant financial relationships | John Wilkins: DO have relevant financial relationships ; Consultant:3M:Active (exists now) | Moyses Szklo: No Answer | Michael Tsai: DO NOT have relevant financial relationships | Seamus Whelton: DO NOT have relevant financial relationships | Laurence Sperling: DO NOT have relevant financial relationships | Sotirios Tsimikas: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Consultant:regeneron:Past (completed) ; Employee:Ionis:Active (exists now) ; Ownership Interest:Kleanthi:Active (exists now) ; Ownership Interest:oxitope:Active (exists now) ; Consultant:Novartis:Active (exists now) | Harpreet Bhatia: DO have relevant financial relationships ; Consultant:Kaneka:Past (completed) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Abbott:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Lipids and Management - A Deep Dive

Saturday, 11/16/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Access to Lipid-Lowering Therapies is Limited by Payer Coverage Restrictions and High Out-of-Pocket Costs on Medicare Prescription Drug Plans

Young Grant, Bansal Kannu, Riello Ralph, Faridi Kamil, Clark Katherine, Desai Nihar

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
Lp(a) and LDL-Cholesterol Interaction Association with Aortic Valve Calcium and Severe Aortic Stenosis

Chew Christopher, Tsimikas Sotirios, Blaha Michael, Whelton Seamus, Marrero Natalie, Jha Kunal, Razavi Alexander, Dzaye Omar, Budoff Matthew, Rotter Jerome, Blumenthal Roger, Bhatia Harpreet

Long-Term Cumulative LDL-C Exposure and ASCVD Events in Young Adults with CAC=0: Insights from the CARDIA Study

Peng Allison, Blaha Michael, Blumenthal Roger, Gianos Eugenia, Razavi Alexander, Bimal Tia, Rubin Maya, Allen Norrina, Wilkins John, Sperling Laurence, Rana Jamal, Whelton Seamus

You have to be authorized to contact abstract author. Please, Login
Not Available